Nektar Therapeutics shares fall 1.61% premarket as cancer research funding faces uncertainty.

Nektar Therapeutics declined 1.61% in premarket trading. The recent news event highlights that federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. This news may have caused investors to be cautious about the stock, leading to the decline.